Scleroderma heart disease.

B. Marasini, M. Massarotti, R. Cossutta

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Heart disease is a frequent and often severe feature of systemic sclerosis (scleroderma). Cardiomyopathy, with ventricular diastolic dysfunction and arrhythmias, is the most important form, since it is associated with a very poor prognosis. The current challenge is to define its pattern and identify individuals at risk, but evaluation in vivo may be hard to perform. The aim of this review is to provide an update on the clinical aspects of scleroderma heart disease and the early pivotal role that coronary microcirculation dysfunction plays in its development. A discussion of the diagnostic tools now available for this frequently asymptomatic condition will be provided. Treatment options will be reviewed, even though no cure for systemic sclerosis exists, and the current therapy of diastolic dysfunction remains unsatisfactory.

Original languageEnglish
Pages (from-to)609-614
Number of pages6
JournalInternational Journal of Immunopathology and Pharmacology
Volume18
Issue number4
Publication statusPublished - Oct 2005

Fingerprint

Systemic Scleroderma
Heart Diseases
Ventricular Dysfunction
Asymptomatic Diseases
Microcirculation
Cardiomyopathies
Cardiac Arrhythmias
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Scleroderma heart disease. / Marasini, B.; Massarotti, M.; Cossutta, R.

In: International Journal of Immunopathology and Pharmacology, Vol. 18, No. 4, 10.2005, p. 609-614.

Research output: Contribution to journalArticle

Marasini, B, Massarotti, M & Cossutta, R 2005, 'Scleroderma heart disease.', International Journal of Immunopathology and Pharmacology, vol. 18, no. 4, pp. 609-614.
Marasini, B. ; Massarotti, M. ; Cossutta, R. / Scleroderma heart disease. In: International Journal of Immunopathology and Pharmacology. 2005 ; Vol. 18, No. 4. pp. 609-614.
@article{3ad7858f0817404eb21f6e58c33910a8,
title = "Scleroderma heart disease.",
abstract = "Heart disease is a frequent and often severe feature of systemic sclerosis (scleroderma). Cardiomyopathy, with ventricular diastolic dysfunction and arrhythmias, is the most important form, since it is associated with a very poor prognosis. The current challenge is to define its pattern and identify individuals at risk, but evaluation in vivo may be hard to perform. The aim of this review is to provide an update on the clinical aspects of scleroderma heart disease and the early pivotal role that coronary microcirculation dysfunction plays in its development. A discussion of the diagnostic tools now available for this frequently asymptomatic condition will be provided. Treatment options will be reviewed, even though no cure for systemic sclerosis exists, and the current therapy of diastolic dysfunction remains unsatisfactory.",
author = "B. Marasini and M. Massarotti and R. Cossutta",
year = "2005",
month = "10",
language = "English",
volume = "18",
pages = "609--614",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "4",

}

TY - JOUR

T1 - Scleroderma heart disease.

AU - Marasini, B.

AU - Massarotti, M.

AU - Cossutta, R.

PY - 2005/10

Y1 - 2005/10

N2 - Heart disease is a frequent and often severe feature of systemic sclerosis (scleroderma). Cardiomyopathy, with ventricular diastolic dysfunction and arrhythmias, is the most important form, since it is associated with a very poor prognosis. The current challenge is to define its pattern and identify individuals at risk, but evaluation in vivo may be hard to perform. The aim of this review is to provide an update on the clinical aspects of scleroderma heart disease and the early pivotal role that coronary microcirculation dysfunction plays in its development. A discussion of the diagnostic tools now available for this frequently asymptomatic condition will be provided. Treatment options will be reviewed, even though no cure for systemic sclerosis exists, and the current therapy of diastolic dysfunction remains unsatisfactory.

AB - Heart disease is a frequent and often severe feature of systemic sclerosis (scleroderma). Cardiomyopathy, with ventricular diastolic dysfunction and arrhythmias, is the most important form, since it is associated with a very poor prognosis. The current challenge is to define its pattern and identify individuals at risk, but evaluation in vivo may be hard to perform. The aim of this review is to provide an update on the clinical aspects of scleroderma heart disease and the early pivotal role that coronary microcirculation dysfunction plays in its development. A discussion of the diagnostic tools now available for this frequently asymptomatic condition will be provided. Treatment options will be reviewed, even though no cure for systemic sclerosis exists, and the current therapy of diastolic dysfunction remains unsatisfactory.

UR - http://www.scopus.com/inward/record.url?scp=33644872768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644872768&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 609

EP - 614

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 4

ER -